



**HAL**  
open science

## Two neurologic facets of CTLA4-related haploinsufficiency

Xavier Ayrignac, Radjiv Goulabchand, Eric Jeziorski, Patricia Rullier, Clarissa Carra-Dallière, Claire Lozano, Pierre Portales, Thierry Vincent, Jean François Viallard, Nicolas Menjot de Champfleur, et al.

► **To cite this version:**

Xavier Ayrignac, Radjiv Goulabchand, Eric Jeziorski, Patricia Rullier, Clarissa Carra-Dallière, et al.. Two neurologic facets of CTLA4-related haploinsufficiency. *Neurology Neuroimmunology & Neuroinflammation*, 2020, 7 (4), pp.e751. 10.1212/NXI.0000000000000751 . hal-03346509

**HAL Id: hal-03346509**

<https://hal.umontpellier.fr/hal-03346509v1>

Submitted on 21 Jan 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

# Two neurologic facets of CTLA4-related haploinsufficiency

Xavier Ayrignac, MD, PhD,\* Radjiv Goulabchand, MD,\* Eric Jeziorski, MD, PhD, Patricia Rullier, MD, Clarissa Carra-Dallière, MD, Claire Lozano, MD, Pierre Portales, MD, Thierry Vincent, MD, PhD, Jean François Viillard, MD, PhD, Nicolas Menjot de Champfleury, MD, PhD, Frédéric Rieux-Laucat, PhD, Caroline Besnard, MD, Michel Koenig, MD, PhD, Claire Guissart, PhD, Pierre Labauge, MD, PhD, and Philippe Guilpain, MD, PhD

## Correspondence

Dr. Ayrignac  
xavier.ayrignac@yahoo.fr

*Neurol Neuroimmunol Neuroinflamm* 2020;7:e751. doi:10.1212/NXI.0000000000000751

## Abstract

### Objective

To describe the clinical and radiologic neurologic characteristics of patients with cytotoxic T-lymphocyte antigen-4 (*CTLA4*) haploinsufficiency.

### Methods

Three patients from 2 families had neurologic manifestations in the context of *CTLA4* haploinsufficiency. Their clinical and MRI findings are presented.

### Results

A 16-year-old boy with a previous diagnosis of combined immunodeficiency presented with severe recurrent episodes of headaches, motor deficit, and seizures associated with waxing and waning gadolinium-enhancing FLAIR cortical/juxtacortical hyperintensities. His sister, who also had combined immunodeficiency, had a brain MRI when she was aged 13 years due to recent headaches and transient right hemianopsia. It revealed a gadolinium-enhancing left occipital white matter hyperintensity. Another 49-year-old woman had progressive visual loss and cerebellar ataxia in the context of recurrent pulmonary infections. All 3 patients were found to have inherited *CTLA4* haploinsufficiency. Patient 1's general condition and neurologic manifestations were completely controlled with abatacept (*CTLA4-Ig*).

### Conclusions

These cases suggest that in addition to the variable clinical penetrance and wide spectrum of *CTLA4* haploinsufficiency, its neurologic spectrum is broad, ranging from recurrent tumefactive lesions to progressive deficits including cerebellar ataxia and optic atrophy with leukoencephalopathy. These phenotypes must be recognized, and should lead to a complete immunologic workup, because potentially effective targeted immunotherapy exists.

\*X. Ayrignac and R. Goulabchand contributed equally to this manuscript as first coauthors.

From the Department of Neurology (X.A., C.C.-D., P.L.), Montpellier University Hospital, INSERM, Univ Montpellier, Montpellier; Internal Medicine Department (R.G.), Caremeau University Hospital, Nîmes; Department of Paediatrics (E.J.), Montpellier University Hospital, INSERM, Univ Montpellier; Médecine interne multi-organes (P.R., P.G.), Montpellier University Hospital, INSERM, Univ Montpellier; Department of Immunology (C.L., P.P., T.V.), Montpellier University Hospital, INSERM, Univ Montpellier; Internal Medicine Department (J.F.V.), Bordeaux University Hospital, Univ Bordeaux; Department of Neuroradiology (N.M.C.), Montpellier University Hospital, INSERM, Univ Montpellier; Université de Paris (F.R.-L., C.B.), Imagine institute, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM UMR 1163, Paris; and Laboratory of Molecular Genetics (M.K., C.G.), Montpellier University Hospital, INSERM, Univ Montpellier, France.

Go to [Neurology.org/NN](https://www.neurology.org/NN) for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

## Glossary

CTLA4 = cytotoxic T-lymphocyte antigen-4; ITP = immune thrombocytopenia.

Cytotoxic T-lymphocyte antigen-4 (CTLA4) is a major negative regulator of T-cell immune response.<sup>1,2</sup> It has recently been shown that heterozygous mutations in the *CTLA4* gene can lead to CTLA4 insufficiency, characterized by a wide range of clinical manifestations including autoimmune diseases, infections, and lymphoproliferation.<sup>3–5</sup> Neurologic manifestations can occur in almost 30% of cases.<sup>5</sup> Nevertheless, their clinical and radiologic characteristics have never been thoroughly described, notably in adult patients.<sup>5,6</sup>

We hereby report on 3 patients from 2 separate families with CTLA4 insufficiency who harbored distinct clinical characteristics, suggesting that its neurologic spectrum is broader than previously suggested.

## Methods

Patients were identified from the reference center for adult-onset inherited leukoencephalopathies, Department of Neurology, Montpellier University Hospital, Montpellier, France.

Clinical and MRI data were analyzed and are described in the article.

## Standard protocol approvals, registrations, and patient consents

Montpellier University Hospital Institutional Review Board approved this study.

## Date availability

Anonymized data will be shared by the corresponding author on reasonable request from any qualified investigator.


## Results

### Case reports

#### Patient 1

A 16-year-old boy (figure 1A, III6) had a previous diagnosis of combined immunodeficiency characterized by autoimmune diseases, repeated skin infections and bacterial pneumonias, and lymphoproliferative disorder (table and figure 1B). The

**Figure 1** Family 1



(A) Family 1 pedigree: the arrow indicates patient 1, squares = males, circles = females, black-filled symbol = symptomatic patients, gray-filled symbol = asymptomatic carrier, and strikethrough = deceased patients. (B) Patient's abdominal and pelvic CT showing enlarged liver and lymph nodes (arrow) (left panel), which decreased (respectively from 213 mm to 190 mm and 23 mm to 18 mm) after abatacept therapy (right panel). (C) Regular brain MRI scans repeated from age 16 to 25 years disclosed multiple nodular cortical/juxtacortical FLAIR hyperintensities (C.a–C.d) with gadolinium enhancement (C.e–C.h). (C.i) Spinal cord MRI evidenced diffuse conus medullaris hyperintensities. (D) Patient 1's sister aged 15 years. The MRI showed an infiltrative occipital white matter lesion with gadolinium enhancement.

**Table** Characteristics of all 3 patients with neurologic involvement

Patient	Patient 1 (III6)	Patient 2 (III8)	Patient 3
<b>Age at onset</b>	5	2	42
<b>Age at onset of autoimmune manifestations</b>	11	2	—
<b>Autoimmune and inflammatory manifestations</b>	ITP  Type 1 diabetes	Type 1 diabetes  Evan syndrome  Bilateral uveitis  Vitiligo  Aseptic meningitis  Autoimmune ovaritis  EBV lymphoproliferative disease	
<b>Autoantibodies</b>	Langerhans islet cell antibodies, antinuclear, antithyroperoxidase, antithyroglobulin, anticardiolipin antibodies, and Coombs test		Rheumatoid factor
<b>Immunologic profile</b>	IgA and IgM insufficiency; low IgG2 and IgG4 subclasses; low T and NK lymphocyte count; low levels of antimeasles and antimumps antibodies	IgG and IgM insufficiency, unmeasurable IgA level; low B and NK lymphocyte count	IgA and IgM insufficiency; reduced IgG2 level and unmeasurable IgG4 level; low B, T, and NK lymphocyte count
<b>Age at onset of repeated infections</b>	5	2	42
<b>Infections</b>	Molluscum contagiosum  Dermatophytosis  Pneumonias  Anal abscess  Septic arthritis  Balanitis	Myocarditis (parvovirus)  Zona  Pneumococcal meningitis  Recurrent bacterial pneumonia	ENT  Lung (bronchiectasis)  Papillomavirus
<b>Lymphoproliferative disorder</b>	Yes  Hepatomegaly and splenomegaly  Multiple lymph node enlargement  Interstitial pneumonitis	Yes  Hepatomegaly and splenomegaly  Multiple lymph node enlargement  Kidney infiltrates  Interstitial pneumonitis	No  —  —

Continued

**Table** Characteristics of all 3 patients with neurologic involvement (*continued*)

Patient	Patient 1 (III6)	Patient 2 (III8)	Patient 3
Age at onset of neurologic symptoms	16	13	49
Neurologic symptoms	Headaches Weakness Partial seizures	Headaches Visual hallucinations	Ataxia Progressive optic atrophy
Brain and spinal cord MRI	Multiple cortical and juxtacortical lesions, FLAIR hyperintense, with gadolinium enhancement	Infiltrative occipital white matter lesion with gadolinium enhancement	Diffuse, bilateral leukoencephalopathy  Cerebellar atrophy

Abbreviations: ENT = ear, nose, and throat; ITP = immune thrombocytopenia; EBV = Epstein-Barr virus; NK = natural killer lymphocytes.

immunologic profile was consistent with a combined immune deficiency (table). When he was aged 16 years, he presented with severe recurrent headaches, but a complete workup including a brain MRI was normal. Since that episode, he had recurrent headaches: at age 21 years, a new brain MRI disclosed multiple hyperintense cortical and juxtacortical FLAIR lesions with gadolinium enhancement (figure 1C). Repeated CSF studies disclosed a high white blood cell count (40–150 cells/ $\mu$ L, lymphocytes) and a high protein level (72–81 mg/dL).

Because of immune thrombocytopenia (ITP), he received repeated courses of oral steroids associated with rituximab. This strategy remained ineffective: his global health status remained unstable with recurrent mucocutaneous bleeding and epistaxis. Two years later, he presented with lower limb weakness and right partial motor seizures. Multiple brain MRIs revealed recurrent brain and spinal cord lesions (figure 1C). A gene panel analysis identified a heterozygous deletion (c.109+1093\_558-513del) in the *CTLA4* gene.

He was then treated with abatacept (CTLA4-Ig), and his general condition progressively improved (complete remission of ITP and bleedings, along with a dramatic reduction in the volume of lymph nodes and liver (figure 1B). Subsequent brain MRI follow-up did not reveal any additional lesions (42 months' follow-up, image not shown).

### Patient 2

Patient 1's sister (figure 1A, III8), who carried the same mutation, had unexplained brain lesions (figure 1D) identified in the context of headaches and transient hemianopsia treated with steroid pulse when she was aged 13 years. From age 2 years, she had been having severe lymphoproliferation, autoimmune manifestations, and multiple infections (table). She was thus diagnosed with combined immunodeficiency. However, for years, multiple immunosuppressive therapies including cyclophosphamide, rituximab, and immunoglobulin supplementation remained ineffective on her global health status. She died at age 16 years due to severe pneumococcal sepsis.

It should be noted that several of their relatives (figure 1A) including their brother and their unaffected father carried the same mutation.

### Patient 3

A 54-year-old woman presented with walking difficulties associated with bilateral axonal optic neuropathy and bladder urgency. Although optic neuropathy progressively worsened, resulting in severe bilateral vision loss (from 160/200 and 140/200 to 30/200 bilaterally within 4 years), she progressively developed severe upper limb dysmetria and speech/swallowing disorders. Clinical examination showed spastic tetraparesis with unsteadiness, marked dysmetria, and head tremor. Cognitive testing was normal. A brain MRI performed at age 55 years identified subtle white matter and

deep basal ganglia FLAIR hyperintensities, as well as cerebellar atrophy and optic atrophy (figure 2, A–D). Another MRI performed 5 years later disclosed a dramatic increase in FLAIR hyperintensities (figure 2, E–H). A complete workup looking for autoimmune, paraneoplastic, and infectious causes was negative. CSF analysis disclosed normal cell count and protein level with 4 CSF-specific oligoclonal bands. A mini-exome analysis identified a heterozygous stop codon within exon 2 of the *CTLA4* gene (c.151C>T; p.Arg51\*).

The patient's previous family history was unremarkable. However, her own medical history revealed recurrent infections going back to when she was aged 40 years. A complete immunologic workup identified both IgA and IgG deficiency. She thus began monthly supplementation with IV immunoglobulin at age 50 years. This treatment regimen contributed to reduce the frequency of ear, nose, and throat as well as lung infections. Treatment with abatacept was initiated in August 2019.

## Discussion

We report a complete description of the clinical and radiologic characteristics of neurologic involvement in the context of *CTLA4* gene haploinsufficiency. These features may occur from the onset of adolescence to late adulthood, either as infiltrating lymphoproliferative lesions or, more surprisingly, as progressive symptoms mimicking genetic neurodegenerative disorders, including progressive cerebellar ataxia and inherited leukoencephalopathies.<sup>5</sup>

Although CNS lesions have been described in almost 30% of patients with *CTLA4* insufficiency, the neurologic spectrum seems to be broad, ranging mainly from autoimmune encephalitis and perivascular lymphocytic infiltration to inflammatory disorders, optic neuritis, and lymphoproliferative disorders


with CNS infiltration.<sup>3–7</sup> Whether our patients' neurologic involvement, notably in patients 1 and 2, is caused by an autoimmune reaction or by a lymphoproliferative process is not clear. Unfortunately, despite the presence of subtle inflammatory CSF changes in patients 1 and 3, it is difficult to favor 1 mechanism, notably in the absence of EBV PCR and pathologic analysis.

Surprisingly, the clinicoradiologic phenotype seen in patient 3 was clearly different from previously published cases, as it was mainly characterized by (1) the progressive development of cerebellar ataxia and visual loss and (2) the presence of bilateral and symmetrical white matter changes, reminiscent of those seen in inherited leukodystrophies/leukoencephalopathies.<sup>8,9</sup> Although we cannot exclude the highly unlikely presence of 2 very rare genetic disorders in a same patient, multiple panel gene excluded the main known causes of inherited leukoencephalopathy, cerebellar ataxia, and mitochondrial diseases.

Although our patients had been diagnosed with combined immunodeficiency years before neurologic manifestations, it is noticeable that in patient 3, the onset of symptoms occurred in her 40s and only preceded neurologic involvement by 5 years. Moreover, it has been suggested that neurologic symptoms can reveal *CTLA4* insufficiency in almost 5% of patients.<sup>5,7</sup> Consequently, irrespective of the neurologic phenotype (which can be extremely varied), *CTLA4* insufficiency and other inherited immunodeficiency should be suspected, whatever the temporal relationship between the onset of systemic and neurologic symptoms. A complete examination and a blood immunologic workup, including a complete lymphocyte phenotyping and IgG subclass measurement, should thus be performed to gather evidence in favor of a potential inherited immunodeficiency.

In addition, the search for *CTLA4* insufficiency is strongly justified by the possibility of using targeted therapy,

**Figure 2** Patient 3's MRI findings



MRI revealed diffuse white matter and basal ganglia FLAIR hyperintensities (A–C and E–G) and cerebellar atrophy (D and H), which progressively worsened from age 52 years (upper panel) to 56 years (lower panel).

i.e., abatacept. Patients 1 and 3 were treated with abatacept, as recently proposed.<sup>5,10</sup> In patient 1, this resulted in a marked improvement of systemic and biological conditions associated with stability of the CNS MRI lesion load. Unfortunately, patient 3's follow-up was too short to identify any meaningful neurologic improvement, but the IV immunoglobulin supplementation could be stopped shortly after the beginning of abatacept treatment.

Our cases suggest that the range of neurologic manifestations associated with CTLA4 insufficiency may be wide and not merely restricted to lymphoproliferative/autoimmune systemic manifestations. Any unexplained neurologic condition consistent with those presented herein, notably in the context of lymphoproliferative disorder, autoimmunity, or immunodeficiency, should benefit from extended workup to identify inherited combined immunodeficiency that can benefit from today's available potentially effective therapy.

### Acknowledgment

The authors thank Teresa Sawyers for reading and revising the English wording of this manuscript.

### Study funding

No targeted funding reported.

### Disclosure

The authors report no disclosures. Go to [Neurology.org/NN](http://Neurology.org/NN) for full disclosures.

### Publication history

Received by *Neurology: Neuroimmunology & Neuroinflammation* March 26, 2020. Accepted in final form April 15, 2020.

### Appendix Authors

Name	Location	Contribution
<b>Xavier Ayrignac, MD, PhD</b>	Montpellier University Hospital	Data collection, design and conceptualization of the study, and drafting and reviewing of the manuscript
<b>Radjiv Goulabchand, MD</b>	Nimes University Hospital	Data collection, design and conceptualization of the study, and drafting and reviewing of the manuscript
<b>Eric Jeziorski, MD, PhD</b>	Montpellier University Hospital	Data collection and drafting and reviewing of the manuscript
<b>Patricia Rullier, MD</b>	Montpellier University Hospital	Data collection and drafting and reviewing of the manuscript
<b>Clarisse Carra-Dallière, MD</b>	Montpellier University Hospital	Data collection and drafting and reviewing of the manuscript

### Appendix (continued)

Name	Location	Contribution
<b>Claire Lozano, MD</b>	Montpellier University Hospital	Data collection and drafting and reviewing of the manuscript
<b>Pierre Portales, MD</b>	Montpellier University Hospital	Data collection and drafting and reviewing of the manuscript
<b>Thierry Vincent, MD, PhD</b>	Montpellier University Hospital	Drafting and reviewing of the manuscript
<b>Jean François Viallard, MD, PhD</b>	Montpellier University Hospital	Drafting and reviewing of the manuscript
<b>Nicolas Menjot de Champfleury, MD, PhD</b>	Montpellier University Hospital	Drafting and reviewing of the manuscript
<b>Frédéric Rieux-Laucat, PhD</b>	Imagine Institute	Data collection and drafting and reviewing of the manuscript
<b>Caroline Besnard, MD</b>	Montpellier University Hospital	Data collection and drafting and reviewing of the manuscript
<b>Michel Koenig, MD, PhD</b>	Montpellier University Hospital	Data collection and drafting and reviewing of the manuscript
<b>Claire Guissart, PhD</b>	Montpellier University Hospital	Data collection and drafting and reviewing of the manuscript
<b>Pierre Labauge, MD, PhD</b>	Montpellier University Hospital	Data collection and drafting and reviewing of the manuscript
<b>Philippe Guilpain, MD, PhD</b>	Montpellier University Hospital	Data collection and drafting and reviewing of the manuscript

### References

- Gardner D, Jeffery LE, Sansom DM. Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. *Am J Transpl* 2014;14:1985–1991.
- Walker LSK, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. *Nat Rev Immunol* 2011;11:852–863.
- Schubert D, Bode C, Kenefick R, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. *Nat Med* 2014;20:1410–1416.
- Kuehn HS, Ouyang W, Lo B, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. *Science* 2014;345:1623–1627.
- Schwab C, Gabrysch A, Olbrich P, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. *J Allergy Clin Immunol* 2018;142:1932–1946.
- Buchbinder D, Seppanen M, Rao VK, Uzel G, Nugent D. Clinical challenges: identification of patients with novel primary immunodeficiency syndromes. *J Pediatr Hematol Oncol* 2018;40:e319–e322.
- Watson LR, Slade CA, Ojaimi S, et al. Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency. *Allergy Asthma Clin Immunol* 2018. Available at: [aacijournal.biomedcentral.com/articles/10.1186/s13223-018-0272-7](http://aacijournal.biomedcentral.com/articles/10.1186/s13223-018-0272-7). Accessed December 15, 2019.
- Labauge P, Carra-Dalliere C, Menjot de Champfleury N, Ayrignac X, Boespflug-Tanguy O. MRI pattern approach of adult-onset inherited leukoencephalopathies. *Neuro Clin Pract* 2014;4:287–295.
- Ayrignac X, Carra-Dalliere C, Menjot de Champfleury N, et al. Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients. *Brain J Neurol* 2015;138:284–292.
- van Leeuwen EM, Cuadrado E, Gerrits AM, Witteveen E, de Bree GJ. Treatment of intracerebral lesions with abatacept in a CTLA4-haploinsufficient patient. *J Clin Immunol* 2018;38:464–467.

# Neurology<sup>®</sup> Neuroimmunology & Neuroinflammation

## Two neurologic facets of CTLA4-related haploinsufficiency

Xavier Ayrignac, Radjiv Goulabchand, Eric Jeziorski, et al.

*Neurol Neuroimmunol Neuroinflamm* 2020;7;

DOI 10.1212/NXI.0000000000000751

This information is current as of June 4, 2020

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://nn.neurology.org/content/7/4/e751.full.html">http://nn.neurology.org/content/7/4/e751.full.html</a>
<b>References</b>	This article cites 9 articles, 2 of which you can access for free at: <a href="http://nn.neurology.org/content/7/4/e751.full.html##ref-list-1">http://nn.neurology.org/content/7/4/e751.full.html##ref-list-1</a>
<b>Citations</b>	This article has been cited by 1 HighWire-hosted articles: <a href="http://nn.neurology.org/content/7/4/e751.full.html##otherarticles">http://nn.neurology.org/content/7/4/e751.full.html##otherarticles</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>All Genetics</b> <a href="http://nn.neurology.org/cgi/collection/all_genetics">http://nn.neurology.org/cgi/collection/all_genetics</a> <b>Leukodystrophies</b> <a href="http://nn.neurology.org/cgi/collection/leukodystrophies">http://nn.neurology.org/cgi/collection/leukodystrophies</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://nn.neurology.org/misc/about.xhtml#permissions">http://nn.neurology.org/misc/about.xhtml#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://nn.neurology.org/misc/addir.xhtml#reprintsus">http://nn.neurology.org/misc/addir.xhtml#reprintsus</a>

*Neurol Neuroimmunol Neuroinflamm* is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.

